GlassScriptPhysician profile
Terri Ann Saunders
NPI 1447724711
$13,635.08
in general payments reported to CMS, 2019-2025
26 companies · $3,889 in 2025
The $3,889 reported for 2025 was more than what 98% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $610 · 2022: $2,414 · 2023: $3,356 · 2024: $3,365 · 2025: $3,889.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $46.91.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,563.90 |
| Education | $46.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $2,093.55 | 2021-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $1,903.76 | 2022-2025 | Uzedy, Austedo Xr, Austedo |
| Otsuka America Pharmaceutical, INC. | $1,446.19 | 2022-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Janssen Pharmaceuticals, INC | $1,362.69 | 2021-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,117.43 | 2022-2025 | Caplyta |
| Alkermes, INC. | $1,105.75 | 2021-2025 | Lybalvi, Aristada |
| Abbvie INC. | $1,046.73 | 2022-2025 | |
| Vanda Pharmaceuticals INC. | $846.78 | 2022-2025 | Fanapt, Hetlioz |
| Axsome Therapeutics, INC. | $530.39 | 2022-2025 | Auvelity |
| Indivior INC. | $339.98 | 2021-2024 | Perseris |
| E.R. Squibb & Sons, L.L.C. | $327.62 | 2024-2025 | Cobenfy |
| Lundbeck LLC | $314.25 | 2022-2025 | Rexulti |
| Gilead Sciences, INC. | $196.04 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $183.56 | 2022-2024 | Quviviq |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $107.73 | 2021-2025 | Rejoyn |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $105.44 | 2022-2025 | Trintellix |
| Acadia Pharmaceuticals INC | $99.16 | 2022-2025 | Nuplazid |
| Esperion Therapeutics, INC. | $90.80 | 2021 | |
| Grt US Holding, INC. | $88.55 | 2022 | |
| Janssen Scientific Affairs, LLC | $77.06 | 2024 | Invega Sustenna |
| Noven Therapeutics, LLC | $67.85 | 2022-2025 | Xelstrym |
| Merck Sharp & Dohme LLC | $66.97 | 2022-2023 | Belsomra |
| Sunovion Pharmaceuticals INC. | $52.15 | 2022 | |
| Supernus Pharmaceuticals, INC. | $30.31 | 2025 | Qelbree |
| Luye Pharma (USA) LTD. | $21.21 | 2025 | Erzofri Extended-Release |
| Eisai INC. | $13.13 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Terri Ann Saunders listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.